The aim of the studyThe aim of the study was to investigate the serum pro-inflammatory cytokine profile in patients with diagnosed endometriosis.Material and methodsThe study included 160 women, who were divided in two study groups (Group I – endometriosis; Group 2 – healthy). We evaluated the serum levels of interleukin (IL)-1β, IL-5, IL-6, IL-7, and IL-12, and of tumour necrosis factor α (TNF-α) with the use of Human Multiplex Cytokine Panels.ResultsThe serum level of IL-1β, IL-6, and TNF-α is significantly higher in women with endometriosis compared to women free of disease, from the control group (mean 10.777, 183.027, and 131.326, respectively, compared to 3.039, 70.043, and 75.285, respectively; p = 0.002, p < 0.001, and p = 0.015, respectively). No significant differences in the serum levels of IL-5 and IL-12 were observed between the studied groups, and IL-7 had a very low detection rate.ConclusionsWomen with endometriosis have elevated levels of key pro-inflammatory cytokines, i.e. IL-1β, IL-6, and TNF-α. At the same time, IL-1β and IL-6 could be used as predictors for endometriosis.
Perimenopause has a variable length and time of onset and is characterized by its variability in hormonal levels. The histological changes in the perimenopausal endometrium may be represented by nonproliferative or proliferative benign or malignant lesions. A commonly encountered manifestation of endometrium lesions during menopausal transition is the abnormal uterine bleeding (AUB). The clinical management of AUB must follow a standardized classification system for optimal results. The medical and surgical treatment must be adapted according to age, risk factors, symptoms, and cycle irregularities. Use of alternative therapies and proper diet may result in improved long-term outcomes.
SUMMARYSmoking during pregnancy is causally associated with reduced birth weight and is strongly related to preterm birth. Smoking cessation in early pregnancy seems to reduce these risks, although the research evidence is limited. In a sample of Romanian women, differences in birth outcomes were assessed between non-smokers and women who continued to smoke during pregnancy and non-smokers and women who stopped smoking when they found out about the pregnancy. Pregnant women were recruited in two urban clinics (N = 474). A baseline questionnaire collected information on their smoking status, depressive symptoms, stress, demographics, and other characteristics at recruitment. The women reported the newborn weight and birth term by phone in the first weeks following birth. Descriptive statistics and multivariate regressions were used to analyze the relationship between smoking status during pregnancy and birth outcomes. Over 61% (N = 290) women were non-smokers, 15% (N = 72) smoked during pregnancy, and 24% (N = 112) quit smoking when they found out about the pregnancy. Compared to non-smokers, continuous smokers delivered babies 165 grams lighter (95% CI −313, −17). Women who stopped smoking when they ascertained the pregnancy had higher odds of delivering a newborn who was small for gestational age compared to non-smokers (OR = 2.16, 95% CI 1.05, 4.43). Elevated maternal stress was associated with reduced birth weight (−113 grams, 95% CI −213, −11), and higher odds of a preterm birth (OR = 2.8, 95% CI 1.17, 6.76). In a predominantly urban sample of Romanian women, continuous maternal smoking during pregnancy was a risk factor for restricted foetal growth. Smoking cessation when the pregnancy was ascertained did not seem to reduce this risk. Smoking prevention efforts should therefore begin before pregnancy and should integrate psychological components, addressing maternal stress in particular.
outcome were significantly increased in infants with abnormal S/D ratio (P < 0.001). When logistic regression analysis was performed after adjusting for gestational age, the odds ratio for poor perinatal outcome was 3.7 in the group showing abnormal S/D ratio (95% confidence interval 1.42-9.54, P = 0.007). Conclusion: Umbilical artery Doppler velocimetry is shown as a significantly efficient method in predicting perinatal outcome in preterm neonates with small-for-gestational age, and it may be useful in managing preterm patients with small-for-gestational age fetuses.Objectives: To show the role of umbilical artery Doppler examination in the evaluation of fetal growth potential and the quantification of various IUGR forms. Material and methods: The study included 116 single pregnancies with suspicion of IUGR following conventional ultrasound (IUGRE). The patients underwent fetal umbilical artery Doppler examination, measuring the RI value. The pregnant women were assigned to two groups: 54 hypertensive pregnancies and 62 non-hypertensive pregnancies. Results: At birth, there were 80 (68.9%) newborns with a weight deficit. The results obtained in non-hypertensive patients: the incidence of fetal weight deficit at birth was 51.6% (12.9% the moderate form, 38.7% the severe form). The reliability of umbilical Doppler examination was Se =68.7%, Sp =93.3%, PPV =91.6%, NPV =73.6%. The results obtained in hypertensive patients: the incidence of fetal weight deficit at birth was 88.8% (25.9% the moderate form and 62.9% the severe form). The reliability of umbilical Doppler examination in the evaluation of fetal growth disorders was Se = 66.6%, Sp = 100%, PPV = 100%, NPV = 27.2%. A 15.5% error percent (8.6% false negative results and 6.9% false positive results) was obtained. Conclusions:In the presence of an ultrasound suspicion of IUGR, an abnormal umbilical RI value allows to confirm the alteration of fetal growth potential. A normal RI value in the context of IUGRE has a different significance depending on the presence or the absence of hypertension. P46.08 Blood flow in pregnancies complicated with IUGR
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.